Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023; 22: 166-176
Антрациклин-индуцированная кардиотоксичность у ребенка с острым лимфобластным лейкозом на фоне новой коронавирусной инфекции
https://doi.org/10.24287/1726-1708-2023-22-3-166-176Аннотация
Химиопрепараты антрациклинового ряда широко используются при лечении различных опухолей, однако они обладают высокой кардиотоксичностью. Новая коронавирусная инфекция также может негативно влиять на функцию сердца. В данной работе представлен клинический случай проявления антрациклинассоциированной кардиотоксичности у ребенка с рефрактерным течением острого лимфобластного лейкоза на фоне присоединения новой коронавирусной инфекции, в котором описана динамика изменения инструментальных и лабораторных показателей в течение лечения, а также приведено описание аутопсийного материала миокарда. Родители пациента дали согласие на использование информации, в том числе микрофотографий, в научных исследованиях и публикациях.
Список литературы
1. Asnani A., Neilan T.G., Tripathy D., Scherrer-Crosbie M. Clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity. 2019. [Электронный ресурс] URL: https://www.uptodate.com/contents/clinical-manifestations-monitoring-and-diagnosis-of-anthracycline-induced-cardiotoxicity. (Аccessed: 07.11.2022).
2. Cardinale D., Colombo A., Bacchiani G., Tedeschi I., Meroni С.А., Veglia F., et al (). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131 (22): 1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777
3. Обрезан А.Г., Щербакова Н.В. Лечение онкологических заболеваний и кардиотоксичность: механизмы возникновения и современные подходы к диагностике сердечной недостаточности у онкологических пациентов. Вопросы онкологии 2019; 65 (2): 172–80.
4. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5 (5): 596–603. DOI: 10.1161/CIRCIMAGING.112.973321
5. Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109 (22): 2749–54. DOI: 10.1161/01.CIR.0000130926.51766.CC
6. Oeffinger K.C., Mertens A.C., Sklar C.A., Kawashima Т., Hudson М.М., Meadows A.T., et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. N Engl J Med 2006; 355 (15): 1572–82. DOI: 10.1056/nejmsa060185
7. Volkova M., Russell R., 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011; 7 (4): 214–20. DOI: 10.2174/157340311799960645
8. Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky В., Scherrer-Crosbie Michael S., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27 (9): 911–39. DOI: 10.1016/j.echo.2014.07.012
9. Armenian S.H., Lacchetti C., Barac A., Carver J., Constine L.S., Denduluri N., et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35 (8): 893–911. DOI: 10.1200/JCO.2016.70.5400
10. Monsuez J.J., Charniot J.C., Vignat N., Artigou J.Y. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010; 144 (1): 3–15. DOI: 10.1016/j.ijcard.2010.03.003
11. Perez I.E., Taveras Alam S., Hernandez,G.A., Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol 2019; 13: 1179546819866445. DOI: 10.1177/1179546819866445
12. Shapira J., Gotfried M., Lishner M., Ravid M. Reduced Cardiotoxicity of Doxorubicin by a 6-Hour Infusion Regimen. A Prospective Randomized Evaluation. Cancer 1990; 65: 870–3.
13. Виценя М.В., Агеев Ф.Т., Гиляров М.Ю., Овчинников А.Г., Орлова Р.В., Полтавская М.Г. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO 2020; 10 (3s2): 81–102.
14. Kalay N., Basar E., Ozdogru I., Er O., Cetinkaya Y., Dogan А., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48 (11): 2258–62. DOI: 10.1016/j.jacc.2006.07.052
15. Auner H.W., Tinchon C., Linkesch W., Tiran А., Quehenberger F., Link H., Sill H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82 (4): 218–22. DOI: 10.1007/s00277-003-0615-3
16. Specchia G., Buquicchio C., Pansini N., Di Serio F., Liso V., Pastore D., et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005; 145 (4): 212–20. DOI: 10.1016/j.lab.2005.02.003
17. Kilickap S., Barista I., Akgul E., Aytemir К., Aksoyek S., Aksoy S., et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16 (5): 798–804. DOI: 10.1093/annonc/mdi152
18. Иванов Д.О., Петренко Ю.В., Резник В.А., Тимченко В.Н., Павлова Е.Б., Чернова Т.М. и др. COVID-19 на фоне острого лимфобластного лейкоза (анализ случая с летальным исходом). ВИЧ-инфекция и иммуносупрессии 2022; 14 (2): 73–82. DOI: 10.22328/2077-9828-2022-14-2-73-82
19. Иванов Д.О., Кондратьев Г.В., Мельников М.Е., Баннова С.Л., Кулева С.А., Петренко Ю.В. и др. Клинический случай длительного персистирования SARS-CoV-2 у младенца с врожденным острым миелоидным лейкозом. Российский журнал детской гематологии и онкологии 2022; 9 (3): 99–106. DOI: 10.21682/2311-1267-2022-9-3-99-106
20. Sanna G., Serrau G., Bassareo P.P., Neroni P., Fanos V., Marcialis M.A. Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review. Eur J Pediatr 2020; 179 (7): 1079–87. DOI: 10.1007/s00431-020-03699-0
21. Dolhnikoff M., Ferreira Ferranti J., de Almeida Monteiro R.A., DuarteNeto A.N., Gomes-Gouvêa M.S., Degaspare N.V., et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health 2020; 4 (10): 790–4. DOI: 10.1016/S2352-4642(20)30257-1
22. Penna A., Khadra N., Tauzin S., Vacher P., Legembre P. The CD95 signaling pathway: To not die and fly. Commun Integr Biol 2012; 5 (2): 190–2. DOI: 10.4161/cib.18888
23. Germanakis I., Kalmanti M., Parthenakis F., Nikitovic D., Stiakaki Е., Patrianakos А., Vardas P.E., et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. International journal of cardiology 2006; 108 (2): 212–5. DOI: 10.1016/j.ijcard.2005.05.006
Pediatric Hematology/Oncology and Immunopathology. 2023; 22: 166-176
Anthracycline-induced cardiotoxicity in a child with acute lymphoblastic leukaemia against the background of new coronavirus infection
https://doi.org/10.24287/1726-1708-2023-22-3-166-176Abstract
Anthracycline chemotherapy drugs are widely used for the treatment of various tumors but they are associated with high cardiotoxicity. The novel coronavirus disease can also negatively affect the heart function. In this article, we report a case of anthracycline-related cardiotoxicity in a child with refractory acute lymphoblastic leukemia and the novel coronavirus disease, describing changes in instrumental and laboratory parameters observed over time during the treatment and providing a description of autopsy samples of the myocardium. The patient’s parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.
References
1. Asnani A., Neilan T.G., Tripathy D., Scherrer-Crosbie M. Clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity. 2019. [Elektronnyi resurs] URL: https://www.uptodate.com/contents/clinical-manifestations-monitoring-and-diagnosis-of-anthracycline-induced-cardiotoxicity. (Accessed: 07.11.2022).
2. Cardinale D., Colombo A., Bacchiani G., Tedeschi I., Meroni S.A., Veglia F., et al (). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131 (22): 1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777
3. Obrezan A.G., Shcherbakova N.V. Lechenie onkologicheskikh zabolevanii i kardiotoksichnost': mekhanizmy vozniknoveniya i sovremennye podkhody k diagnostike serdechnoi nedostatochnosti u onkologicheskikh patsientov. Voprosy onkologii 2019; 65 (2): 172–80.
4. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5 (5): 596–603. DOI: 10.1161/CIRCIMAGING.112.973321
5. Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109 (22): 2749–54. DOI: 10.1161/01.CIR.0000130926.51766.CC
6. Oeffinger K.C., Mertens A.C., Sklar C.A., Kawashima T., Hudson M.M., Meadows A.T., et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. N Engl J Med 2006; 355 (15): 1572–82. DOI: 10.1056/nejmsa060185
7. Volkova M., Russell R., 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011; 7 (4): 214–20. DOI: 10.2174/157340311799960645
8. Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky V., Scherrer-Crosbie Michael S., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27 (9): 911–39. DOI: 10.1016/j.echo.2014.07.012
9. Armenian S.H., Lacchetti C., Barac A., Carver J., Constine L.S., Denduluri N., et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35 (8): 893–911. DOI: 10.1200/JCO.2016.70.5400
10. Monsuez J.J., Charniot J.C., Vignat N., Artigou J.Y. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010; 144 (1): 3–15. DOI: 10.1016/j.ijcard.2010.03.003
11. Perez I.E., Taveras Alam S., Hernandez,G.A., Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol 2019; 13: 1179546819866445. DOI: 10.1177/1179546819866445
12. Shapira J., Gotfried M., Lishner M., Ravid M. Reduced Cardiotoxicity of Doxorubicin by a 6-Hour Infusion Regimen. A Prospective Randomized Evaluation. Cancer 1990; 65: 870–3.
13. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., Ovchinnikov A.G., Orlova R.V., Poltavskaya M.G. Prakticheskie rekomendatsii po korrektsii kardiovaskulyarnoi toksichnosti protivoopukholevoi lekarstvennoi terapii. Prakticheskie rekomendatsii RUSSCO 2020; 10 (3s2): 81–102.
14. Kalay N., Basar E., Ozdogru I., Er O., Cetinkaya Y., Dogan A., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48 (11): 2258–62. DOI: 10.1016/j.jacc.2006.07.052
15. Auner H.W., Tinchon C., Linkesch W., Tiran A., Quehenberger F., Link H., Sill H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82 (4): 218–22. DOI: 10.1007/s00277-003-0615-3
16. Specchia G., Buquicchio C., Pansini N., Di Serio F., Liso V., Pastore D., et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005; 145 (4): 212–20. DOI: 10.1016/j.lab.2005.02.003
17. Kilickap S., Barista I., Akgul E., Aytemir K., Aksoyek S., Aksoy S., et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16 (5): 798–804. DOI: 10.1093/annonc/mdi152
18. Ivanov D.O., Petrenko Yu.V., Reznik V.A., Timchenko V.N., Pavlova E.B., Chernova T.M. i dr. COVID-19 na fone ostrogo limfoblastnogo leikoza (analiz sluchaya s letal'nym iskhodom). VICh-infektsiya i immunosupressii 2022; 14 (2): 73–82. DOI: 10.22328/2077-9828-2022-14-2-73-82
19. Ivanov D.O., Kondrat'ev G.V., Mel'nikov M.E., Bannova S.L., Kuleva S.A., Petrenko Yu.V. i dr. Klinicheskii sluchai dlitel'nogo persistirovaniya SARS-CoV-2 u mladentsa s vrozhdennym ostrym mieloidnym leikozom. Rossiiskii zhurnal detskoi gematologii i onkologii 2022; 9 (3): 99–106. DOI: 10.21682/2311-1267-2022-9-3-99-106
20. Sanna G., Serrau G., Bassareo P.P., Neroni P., Fanos V., Marcialis M.A. Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review. Eur J Pediatr 2020; 179 (7): 1079–87. DOI: 10.1007/s00431-020-03699-0
21. Dolhnikoff M., Ferreira Ferranti J., de Almeida Monteiro R.A., DuarteNeto A.N., Gomes-Gouvêa M.S., Degaspare N.V., et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health 2020; 4 (10): 790–4. DOI: 10.1016/S2352-4642(20)30257-1
22. Penna A., Khadra N., Tauzin S., Vacher P., Legembre P. The CD95 signaling pathway: To not die and fly. Commun Integr Biol 2012; 5 (2): 190–2. DOI: 10.4161/cib.18888
23. Germanakis I., Kalmanti M., Parthenakis F., Nikitovic D., Stiakaki E., Patrianakos A., Vardas P.E., et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. International journal of cardiology 2006; 108 (2): 212–5. DOI: 10.1016/j.ijcard.2005.05.006
